Genetic Maps Target Root Causes of Multiple Sclerosis

May 18, 2026

Summary: A milestone neurobiology study has provided the first empirical, direct comparison of the two leading preclinical models used to study multiple sclerosis (MS). Investigating the destruction and regeneration of myelin, the protective fatty sheath surrounding nerve fibers, the research group analyzed the cuprizone (CPZ) and lysophosphatidylcholine (LPC) paradigms alongside real human MS tissue samples.

By utilizing single-cell RNA sequencing to map genetic alterations during demyelination, the study shatters the assumption that these models are interchangeable, providing a definitive scientific roadmap to help researchers choose the correct model for targeted MS drug development.

Key Facts

• The Myelin Insulator: Multiple sclerosis affects over 1 million Americans, causing the immune system to mistakenly strip away myelin, the protective coating that insulates neural axons like plastic around electrical wires.
• The Preclinical Mandate: Because collecting viable, live brain and spine tissue from progressive MS patients is exceptionally challenging, science relies heavily on preclinical animal models to test therapeutic concepts.
• Deconstructing CPZ vs. LPC: While both paradigms induce demyelination, they operate on wildly different structural and chronological scales; CPZ triggers widespread myelin loss over several weeks, whereas LPC induces a single, highly localized lesion within days.
• Cellular Specificity Guidance: The study proves CPZ is superior for analyzing the stress, death, and repair mechanics of myelin-producing cells due to its gradual timeline. Conversely, LPC is optimal for mapping aggressive, acute autoimmune responses.
• Genetic Mapping to Human Tissue: The research group built single-cell genetic maps of the lesions from both models and matched them directly against human MS tissue to ensure future treatments are clinically relevant.
• The Unreached Therapeutic Frontier: Modern MS drugs focus almost exclusively on suppressing autoimmune flare-ups; physically regenerating lost myelin within established neural lesions remains a promising but currently unrealized medical target.

Source: University of Notre Dame

More than 1 million people across the United States live with multiple sclerosis (MS), a disease that affects the brain, optic nerves and spine.

CLICK here to Read MORE

CLICK HERE to help us to continue our mission of providing relevant MS related information so the MS community stays informed.

—————————-